targeted therapy

2019 ASCO ® Annual Meeting; #ASCO19
June 3, 2019
Greg Guthrie, ASCO staff

ASCO Annual Meeting 2019: Laparoscopic Surgery for Metastatic Colorectal Cancer, Expanding Eligibility Criteria for Advanced Non-Small Cell Lung Cancer, and a New Targeted Therapy for Advanced Bladder Cancer

English
gregguthrie

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include minimally invasive surgery for liver metastases in colorectal cancer, expanding clinical trial eligibility criteria for non-small cell lung cancer, and a new targeted therapy for advanced bladder cancer.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
June 2, 2019
Monika Sharda, ASCO staff

ASCO Annual Meeting 2019: Treatment Advances for Metastatic Prostate Cancer and Pancreatic Cancer, Multiple Myeloma Survival Factors, and Effects of the Affordable Care Act on Cancer Care

English
Monika.Sharda

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
May 15, 2019
Greg Guthrie, ASCO staff

ASCO Annual Meeting 2019: An Early Look at This Year’s Research

English
gregguthrie

Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.

Read More >>
ASCO ® American Society of Clinical Oncology; Clinical Cancer Advances 2019: ASCO's Annual Report on Progress Against Cancer
January 31, 2019
Greg Guthrie, ASCO Staff

Progress in Treating Rare Cancers: The 2019 Advance of the Year

English
Greg Guthrie

In 2019, ASCO recognizes the progress in treating rare cancers as the Advance of the Year. Impressive progress has been made in bringing new treatment advances to cancers that are rare and difficult to treat. This year’s Clinical Cancer Advances report describes emerging treatments for thyroid cancer, uterine cancer, desmoid tumor, neuroendocrine tumor, and tenosynovial giant cell tumor.

Read More >>

Pages

Subscribe to RSS - targeted therapy